Fact based stock research
Revance Therapeutics (NasdaqGM:RVNC)

US7613301099



Research has been discontinued due to acquisition by Crown Laboratories.



How to read the free ranks

For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. The higher the rank, the better the stock performs than its peers. And, we do this for six investment strategies:
Value - shows how good of a value the stock is. Green is "inexpensive"; red is "expensive".

Growth - shows a company's growth potential. Green is "high growth" expected; red is "tough times ahead".

Safety - relates to the amount of debt a company has. Green is low debt level; red is high debt level.

Combined Financial - this isn't an average of the first three ranks but rather a consolidated view across several financial indicators. Green = good; red = tread carefully.

(NEW) Sentiment - quantifies professional analyst ratings and holdings as well as market pulse. Green = positive sentiment; red = skepticism (Only available to Premium Subscribers).

(NEW) 360° View - the ultimate rating with all financial and non-financial indicators.

Revance Therapeutics stock research in summary

revance.com


n/a
n/a

Latest Obermatt Ranks


Log in or sign up to see the new 360° View and Sentiment ranks.

360° Viewnew
Sentiment Ranknew
Value Rank n/a
Growth Rank n/a
Safety Rank n/a
Combined Rank n/a
Country USA
Industry Pharmaceuticals
Index NASDAQ
Size class Small

. Stock data may be delayed. Log in or sign up to get the most recent research.

Add to Watchlist
See Similar Stocks
Subscribe to updates


Multiple opinions. One number.

Analysts rarely agree on a stock’s future. So, who do you believe? Obermatt translates those collective views into a single Sentiment Rank. That plus the financial ranks give you the ultimate 360° View. Sign up to access them.
Why popular stocks have low ratings

It’s easier said than done. When your stock drops, it’s easy to want to sell it and find a better performer. Think twice, or even three times, before trading. Those fees (especially the hidden ones) can eat up your gains.

Review the performance ranks of the individual metrics that form each investment strategy.

Research History: Revance Therapeutics

RESEARCH HISTORY 2022 2023 2024 2025
VALUE
VALUE 5
78
82
n/a
GROWTH
GROWTH 21
37
65
n/a
SAFETY
SAFETY 41
25
22
n/a
SENTIMENT
SENTIMENT 100
48
12
new
360° VIEW
360° VIEW 31
28
44
new

Most recent update of the stock research: . Financial reporting date used for calculating ranks: . Stock research history is based on the Obermatt Method. The higher the rank, the better Revance Therapeutics is in the corresponding investment strategy.
Upgrade to a Premium Account to access the latest ranks.


Combined financial peformance in Detail

n/a n/a
RESEARCH HISTORY 2022 2023 2024 2025
VALUE
VALUE 5
78
82
n/a
GROWTH
GROWTH 21
37
65
n/a
SAFETY
SAFETY 41
25
22
n/a
COMBINED
COMBINED 4
42
74
n/a

Last update of combined financial performance: . Stock analysis on combined financial performance: The higher the rank of Revance Therapeutics the better the performance.


Value Metrics in Detail

n/a n/a
VALUE METRICS 2022 2023 2024 2025
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S) 29
64
76
n/a
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E) 6
94
94
n/a
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book) 10
94
92
n/a
DIVIDEND YIELD
DIVIDEND YIELD 1
1
1
n/a
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE 5
78
82
n/a

Last update of Value Rank: . Stock analysis on value ratios: The higher the rank, the lower the value ratio of Revance Therapeutics; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

n/a n/a
GROWTH METRICS 2022 2023 2024 2025
REVENUE GROWTH
REVENUE GROWTH 79
87
94
n/a
PROFIT GROWTH
PROFIT GROWTH 41
51
48
n/a
CAPITAL GROWTH
CAPITAL GROWTH 5
12
60
n/a
STOCK RETURNS
STOCK RETURNS 29
17
29
n/a
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH 21
37
65
n/a

Last update of Growth Rank: . Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Revance Therapeutics.


Safety Metrics in Detail

n/a n/a
SAFETY METRICS 2022 2023 2024 2025
LEVERAGE
LEVERAGE 53
7
5
n/a
REFINANCING
REFINANCING 49
77
77
n/a
LIQUIDITY
LIQUIDITY 15
22
21
n/a
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY 41
25
22
n/a

Last update of Safety Rank: . Stock analysis on safety metrics: The higher the rank, the lower the leverage of Revance Therapeutics and the more cash is available to service its debt.


Sentiment Metrics in Detail

SENTIMENT 2022 2023 2024 2025
ANALYST OPINIONS
ANALYST OPINIONS n/a
47
5
new
OPINIONS CHANGE
OPINIONS CHANGE 94
50
50
new
PRO HOLDINGS
PRO HOLDINGS 86
59
1
new
MARKET PULSE
MARKET PULSE 64
45
21
new
CONSOLIDATED RANK: SENTIMENT
CONSOLIDATED RANK: SENTIMENT 100
48
12
new

Last update of Sentiment Rank: . Stock analysis on sentiment metrics: The higher the rank, the more positive the sentiment for Revance Therapeutics.
Upgrade to a Premium Account to access the latest ranks.


Add to Watchlist
See Similar Stocks
Subscribe to updates

Free stock analysis by the purely fact based Obermatt Method for Revance Therapeutics from February 27, 2025.

Obermatt Portfolio Performance
We’re so convinced about our free research, that we buy our stock tips.
See the performance of the Obermatt portfolio.